Avalo Therapeutics, Inc.

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-16 EDT			5-day change	1st Jan Change
12.5 ^USD	-1.19%		-2.80%	+37.36%

07-16	Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer	CI
07-09	Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa	CI

Cerecor Announces U.S. Headquarters Move into Pharmaceutical Corridor of Rockville, Maryland

January 28, 2019 at 06:30 am

Cerecor Inc. announced that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.

Latest news about Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer	07-16	CI
Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa	07-09	CI
Avalo Therapeutics Names Chief Legal Officer	06-24	MT
Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer	06-24	CI
Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
North American Morning Briefing : Stock Futures -2-	04-17	DJ
Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	04-16	MT
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Sector Update: Health Care Stocks Rise Late Afternoon	03-28	MT
Top Midday Gainers	03-28	MT
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	03-28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	03-28	MT
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	03-28	MT
Top Premarket Gainers	03-28	MT
Avalo Therapeutics, Inc. announced that it has received $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, BVF Partners L.P., RA Capital Management, L.P., Commodore Capital LP, Petrichor Holdings, LLC	03-27	CI
Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.	03-27	CI
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing of Up to $185 Million	03-27	MT
Avalo Therapeutics, Inc. Announces Board Appointments	03-27	CI
North American Morning Briefing : Stocks Edge -2-	03-27	DJ
Avalo Therapeutics, Inc. announced that it expects to receive $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Commodore Capital, BVF Partners L.P., Petrichor Energy Inc., RA Capital Management, L.P.	03-26	CI
Avalo Therapeutics Plans 1-for-240 Reverse Stock Split	12-27	MT
Avalo Therapeutics, Inc. announced that it has received $2.354585 million in funding	12-13	CI
Avalo Therapeutics, Inc. announced that it expects to receive $2.129586 million in funding	11-21	CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	11-13	DJ
Avalo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI

Chart Avalo Therapeutics, Inc.

Duration

Period

More charts

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1Î² mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1Î² (IL-1Î²) with high affinity and neutralizes its activity. IL- 1Î² is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.5 USD

Average target price

35 USD

Spread / Average Target

+180.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVALO THERAPEUTICS, INC.	+37.36%	13.08M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research

Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Biotechnology & Medical Research

Cerecor Announces U.S. Headquarters Move into Pharmaceutical Corridor of Rockville, Maryland

Latest news about Avalo Therapeutics, Inc.

Chart Avalo Therapeutics, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research